Molecular characterization of human and bovine endothelin converting enzyme (ECE-1)  by Schmidt, Martin et al.
FEBS Letters 356 (1994) 238-243 
FEBS 14890 
Molecular characterization of human and bovine endothelin converting 
enzyme (ECE- 1) 
Martin Schmidt”,*, Burkhard Kriiger”, Elard Jacoba, Harald Seulberger”, Thomas Subkowski”, 
Rainer Otter”, Thomas Meyera, Giinther Schmalzingb, Heinz Hillen” 
“Department of Pharmaceutical Research, BASF Aktiengesellschaft, D-67056 Ludwigshafen, Germany 
bMax-Planck-Institute for Biophysics, D-60528 Frankfurt, Germany 
Received 31 October 1994 
Abstract A membrane-bound protease activity that specifically converts Big endothelin-1 has been purified from bovine endothelial cells (FBHE). 
The enzyme was cleaved with trypsin and the peptide sequencing analysis confirmed it to be a zinc chelating metalloprotease containing the typical 
HEXXH (HELTH) motif. RT-PCR and cDNA screens were employed to isolate the complete cDNAs of the bovine and human enzymes. This human 
metalloprotease was expressed heterologously in cell culture and oocytes. The catalytic activity of the recombinant enzyme is the same as that 
determined for the natural enzyme. The data suggest hat the characterized enzyme represents the functional human endothelin converting enzyme 
ECE-1. 
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1. Introduction 
Endothelin, ET, was first characterized as an endothelium- 
derived contracting factor (EDCF) [l] and subsequently puri- 
fied and sequenced [2]. Endothelin-1 (ET-l) is regarded as the 
most important vasoconstrictor of the three identified isopep- 
tides ET-l, -2, -3 [3], is synthesized by vascular endothelial cells 
[2] and is found in plasma. There are a number of diseases in 
which ET-l is thought to play a role [4]. By means of specific 
ET-l receptor antagonists and endothelin specific antibodies it 
has been possible to demonstrate in animal models an involve- 
ment of ET-l in pathological situations such as acute renal 
failure and subarrachnoid hemorrhage [5-71. Besides its poten- 
tial role in cardiovascular diseases, ET-l has been shown to be 
essential for normal development [8]. 
ET-l is released from an inactive intermediate form called 
Big-ET-l. This step is catalyzed by a putative endothelin con- 
verting enzyme (ECE), as has been hypothesized by Yana- 
gisawa and coworkers [2], and much effort has been directed 
towards the molecular characterisation of this enzyme. Various 
proteases have been implicated in the processing of Big-ET-l 
to ET-l [9] but recent literature has focused on a metallopro- 
tease as the physiologically relevant enzyme [l&14] which is 
found mainly in endothelial cells. ECE activity and the secre- 
tion of ET-l can be inhibited unselectively by phosphoramidon 
which is a more powerful inhibitor of neutral endopeptidase 
(NEP 3.4.24.11). However, ECE-activity can be differentiated 
from that of NEP 3.4.24.11 by means of specific NEP 3.4.24.11 
inhibitors which do not interfere with the effects of Big-ET-l 
in vivo and which do not inhibit the secretion of ET-l from 
endothelial cells [15-181. ECE-1 can be defined as a phospho- 
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ramidon inhibitable endopeptidase which cleaves Big-ET-l be- 
tween Trp”and Val**. Using this definition several groups have 
characterized this enzyme. With respect to the enzymatic activ- 
ity of ECE, there has been more agreement in the literature (K,,, 
Big-ET-l = lo-’ M; ICs, Phosphoramidon = 3-10pM) than on 
the molecular characterization of ECE, e.g. the molecular 
weight of the putative ECE has been estimated to be 100-350 
kDa [ 10,12-141. Although ECE has been repeatedly character- 
ized as a membrane-bound enzyme, there have also been re- 
ports suggesting its location in the cytosol [9]. In the absence 
of specific ECE-inhibitors, the characterization of ECE and its 
distinction from other endoproteinases is a prerequisite in the 
evaluation of its role in physiological and pathological condi- 
tions. 
2. Materials and methods 
2. I. Cell culture 
FBHE bovine heart endothelial cells were obtained from the ATCC 
(CRL 1395) and cultured in DMEM +10% FCS +25 &ml bFGF 
(Intergen). Cells were passaged twice a week. Two days before harvest, 
10m4 M phosphoramidon (Peptide Inst.) was added to the cell culture 
medium. Phosphoramidon had no influence on the growth of the cells. 
Cells were harvested by scraping and concentrated by centrifugation. 
The resulting cell suspension was washed with PBS. 
CHO-Kl cells were obtained from the ATCC (CCMI) and cultured 
in DMEMIF12 + 10% FCS. 
2.2. Enzyme assay 
1~1 of individual fractions was diluted into 21~1 of 50 mM Tris-HCI 
pH 7.4; 50 mM imidazole; 250 mM NaCl and added to 2.5 ~1 human 
Big-ET-l (2 mg/ml in 0.1% acetic acid). After a 4 h incubation at 37” C 
the reaction was stopped by adding 72 ~10.5% trifluoro-acetic acid and 
samples were analyzed for ET-l by reversed-phase HPLC on an 
Aquapore C8 column. ET-l was quantified (1 PU = 10m6 PM 
ET-I x min-‘) from the HPLC areas (UVZo8 .,) by calibration with 
standard ET-l. A similar analysis was performed for the other peptide 
substrates (Big-ET-2 and Big-ET-3). Protein concentrations were deter- 
mined after Bradford [19]. 
2.3. Enzyme purification 
A pellet of 5 x 10’ FBHE cells, which had been incubated for two 
days in the presence of 10m4 M phosphoramidon, was resuspended in 
PBS, supplemented with 0.5 mM DIFP and sonicated (20 min, O’C). 
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After a 20 min, 1000 x g centrifugation, the membrane fraction was 
isolated from the supernatant by 1 h ultracentrifugation at 100,000 x g. 
Membranes were solubilized in 0.1 M Tris-HCl pH 8.0; 1% Triton 
X-100 and chromatographed on a MonoQ-HR 515 column (Pharmacia) 
eauilibrated with buffer A (0.5 M Tris-HCl uH 8.0: 0.1% Triton X-100). 
ECE-1 was eluted with a linear gradient from buffer A to buffer A + ‘1 
M NaCl. Fractions containing ECE-1 activity were pooled and chroma- 
tographed on a Superose-12 HR lo/36 column (Pharmacia) in 20 mM 
sodium phosphate buffer pH 7.4; 250 mM NaCI; 0.05% Triton X-100. 
2.4. SDS-PAGE and tryptic digestion in the gel 
Fractions of Superose-12 column separations were run on an 8% 
SDS-PAGE under non-reducing conditions and the gel was stained 
with Coomassie brilliant blue. Gel slices containing about 100 pmol of 
the 250 kDa protein were excised, destained in water and equilibrated 
with 200 ~1 of 0.1 M NH4HC0,. 0.5 pg trypsin was added and after an 
overnight incubation at room temperature the supematant was har- 
vested. The procedure was repeated and the combined supernatants 
were freeze-dried, dissolved in 40 ~1 water, 4 ~140 mM DTT, after 30 
min 4 ~1 100 mM iodine acetamide in PBS was added and stirred for 
a further 30 min. The samples were freeze-dried and redissolved in 0.5% 
trifluoro acetic acid (TFA). Tryptic peptides were chromatographed on 
a RP 8 column (Brownlee, 1 mm xl 5 cm) with a linear g&Ii&t from 
0.5% TFA in H,O to 0.5% TFA in acetonitrile/H,O (9: 1). A total of 
25 fractions were collected and each fraction of 5Oil was analyzed with 
a gas-phase sequencer (477A, Applied Biosystems). 
2.5. ECE-1 cDNA cloning 
Tryptic peptide 4 was backtranslated to synthesize degenerate prim- 
ers A, (S-GARATYGTSTTYCCYGCYGG-3’) and B, (5’-ATYCTS- 
CAGGCYCCYTTYTAYAC-3’). For RT-PCR, total RNA was recov- 
ered from phosphoramidon-treated FBHE cells and reverse transcribed 
with primer (5’-CGAGGGGGATGGTCGACGGAAGCGACCT,8- 
3’). First strand cDNA was amplified in a nested set RACE-PCR f20] 
reaction as described previously [21] using primer A and primer (5’: 
CGAGGGGGATGGTCGACGG-31. The nroducts were senarated 
on agarose gels and DNA fragments from fractionated slices were 
amplified in a second PCR with primer B and primer (5’-GATGGT- 
CGACGGAAGCGACC-3’). A 1 kb frazment. which was generated. 
was non-isotopically labelled according-to DIG DNA labelling kit 
(Boehringer Mannheim) and used to screen a FBHE cDNA library 
(prepared according to Stratagene UniZAP cloning kit) as well as a 
human placenta lgtl 1 cDNA library (Clontech). The resulting clones 
were sequenced and yielded the cod&regions from aa 47-754(bovine 
cDNA) and aa 51-753 (human cDNA). To comalete the cDNAs. PCR 
reactions were performed on a bovine lung cDNA in 1gtll and an 
internally primed human placenta cDNA in AUniZAP with nested 
internal antisense primers and ;1 vector primers. All sequences were 
determined on both strands. The sequences have been deposited with 
the EMBL/Genbank/DDBJ databases and assigned the accession um- 
bers 235306 and 235307. 
2.6. Northern analysis 
A human tissue Northern blot, containing approx. 2 pug of polyA’ 
RNA per tract, was hybridized under standard conditions with a 32P- 
labelled DNA-probe (specific activity s IO’ Bq/pg) representing the 
rezion between amino acids 610-702 of human ECE-1 cDNA. The blot 
was washed in 0.1 x SSC, 0.5% SDS at 65°C and exposed to X-ray film 
at -70°C overnight. 
Table 1 
Purification of ECE-1 from bovine endothelial cells (FBHE) 
Purification Protein Activity Yield Specific 
step (mg) WJ) (8) activity 
WJ~mg) 
Membranes 87 35.600 100 410 
Solubilisate 88 31,460 88 360 
MonoQ 6.6 24,800 69 3,760 
Superose-12 0.35 5,280 15 15,100 
For experimental details see section 2. The determination of the enzy- 
matic activity is described in section 2.2. 
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Fig. 1. SDS-PAGE and tryptic digestion in the gel. Fractions of Super- 
ose-12 columns separations were run on an 8% SDS-PAGE under 
non-reducing conditions and the gel was stained with Coomassie bril- 
liant blue. The arrow denotes the 250 kDa band identified as ECE-1. 
2.7. Heterologous expression of recombinant ECE-I 
Recombinant human ECE was expressed in CHO-cells using 
pcDNA3neo (Invitrogen, Prod. #V790-20) as expression vector and 
the entire coding region of human ECE-1 cDNA including 420 bp of 
3’untranslated region. A similar construction was performed for 
oocyte injection with the in vitro transcription vector pSP73 (Promega 
Corp., Prod. #P2221). In this case a synthetic polyA-stretch and a 
unique MIuI site were added to the 3’ region. The cDNA was tran- 
scribed in vitro with SP6 polymerase. after linearization of the plasmid 
with MluI. 
CHO-Kl cells were transfected using lipofectamine (Gibco) and se- 
lected with G418. Resistant colonies were pooled, expanded and har- 
vested. Solubilization and enrichment was performed using the 
MonoQ-HR 515 column described in section 2.3. ECE-acitivity was 
measured as described in section 2.2. IC,, is the phosphoramidon con- 
centration at which ECE activity is inhibited by 50%. 
3. Results and discussion 
Membrane preparations of permanent bovine endothelial 
cells (FBHE) contain a Big-ET-l specific converting activity 
that can be inhibited by phosphoramidon. Interestingly, we 
found that membranes prepared from FBHE cells which were 
previously treated with phosphoramidon, showed an up to ten- 
fold increase in specific activity for Big-ET-l conversion (man- 
uscript in preparation). A similar effect was also seen with other 
cell lines, although to a lesser extent (3- to 5-fold, data not 
shown). Phosphoramidon is a competitive inhibitor of low 
binding affinity for ECE. It easily dissociates from ECE during 
the first purification steps. This activity was solubilized, puri- 
fied and differentiated against Big-ET-2/-3 conversion (Table 
1). ECE-1 activity from the gel filtration step was separated on 
SDS-PAGE gels under non-reducing conditions (Fig. 1). A 
prominent 250 kDa band was correlated with ECE-1 by three 
different means: (1) the 250 kDa band showed up only after 
purification from phosphoramidon-treated cells but not from 
untreated cells; (2) the intensity of the stained band matched 
exactly the activity measured in different fractions; (3) digestion 
with chymotrypsin, which affects the activity of the enzyme, led 
to the disappearance of the 250 kDa band; whereas, under 
limited conditions, papain and trypsin, that affected only unre- 
lated proteins, had neither an effect on the activity nor on the 
disappearance of this band (data not shown). Therefore, we 
concluded that this band contained ECE-1. Another report has 
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described ECE-activity for a protein of approx. 250-280 kDa 
[14] which might correspond to the ECE described in this paper. 
The putative ECE-1 from FBHE-membrane fractions displays 
an apparent molecular weight of 120 kDa as determined in 
polyacrylamide gels under reducing conditions (data not 
shown). ECE-1 appears to be glycosylated, as the slightly dif- 
fuse 120 kDa band was transformed into a sharp band of about 
85 kDa after deglycosylation with a mixture of peptide-N-gly- 
cosidase F and endoglycosidase F (data not shown). 
To prove these hypotheses, we cloned and expressed the 
cDNA coding for ECE-1. To this end, the protein band of 250 
kDa under non-reducing conditions was excised and the pro- 
tein in the gel was digested with trypsin. The amino acid se- 
quences of the peptide products were analyzed on a gas-phase 
sequencer after separation on reversed phase HPLC. The 
amino acid sequences of several tryptic peptides are shown in 
Fig. 2. Among those, SSPNALNFGGIGVVVGHELTHAF 
was indicative of the presence of a metalloprotease, since it 
contained the putative active site, zinc-chelating HEXXH- 
motif. The peptide sequence NEIVFPAGILQAPFYT (4 in 
Fig. 2) was used to deduce two degenerate oligonucleotide 
primers (see section 2) in order to to follow a nested set RT- 
PCR strategy. First strand cDNA was synthesized from total 
RNA from phosphoramidon-treated FBHE cells with the help 
of a composite oligo-dT-primer (see Fig. 2) and used as a 
template. During the nested set PCR a 1 kb product was ampli- 
fied. After subcloning, this DNA fragment was sequenced and 
the presence of other tryptic peptides (5, 6 and 7 in Fig. 2) in 
the open reading frame confirmed it to be a partial cDNA 
coding for the enzymatic activity described above. The same 
Fig. 2 (a and b). Nucleotide and amino acid sequences of human and bovine ECE-1. (c) Comparison of the amino acid sequences of human and 
bovine ECE-1. Underlined residues correspond to sequenced peptides, and are numbered at the N-terminus. The resulting open reading frames of 
the cDNA clones from both species are aligned and amino acids in lower case denote differences between the species. Amino acids which have been 
shown for NEP 3.4.24.11 to be involved in ligand binding and have been conserved in ECE are indicated with bold letters. Potential glycosylation 
sites are denoted by asterisks. 
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Fig. 2 (continued). 
1 kb fragment was used to screen an FBHE- and a human 
placenta cDNA library. Since the isolated clones from both 
screens did not contain the entire coding region, a combination 
of S-RACE and additional screens were employed. 
The resulting open reading frames are displayed in Fig. 2. 
The human and bovine cDNAs encode proteins of 753 and 754 
amino acids, respectively, corresponding to approx. 85 kDa. 
This size is identical to that of natural ECE-1 after deglycosyl- 
ation and analyzed under reducing conditions. Since all se- 
quenced peptides derived from the 250 kDa band by tryptic 
digestion were found in the coding sequence, we concluded that 
homodimerisation of ECE-1 was a reasonable assumption. In 
addition, immunoprecipitated recombinant ECE-1 from mem- 
branes of metabolically labeled Xenopus oocytes displays the 
same 250 kDa band under non-reducing conditions and a 120 
kDa band under reducing conditions that we observed with the 
protein from natural sources (data not shown). Therefore, we 
assume that human ECE-1 is a homodimeric membrane pro- 
tein. 
With the exception of an additional amino-terminal methion- 
ine in the bovine ECE-1 coding sequence, both sequences are 
colinear with a high degree of conservation (94% identity). In 
a comparison of the amino acid sequence of the rat endothelin 
converting enzyme published by Shimada and coworkers [22] 
with the human amino acid sequence presented in this study, 
we observed a similar high degree of conservation (95% iden- 
tity). 
Recently, Yanagisawa and coworkers [23] published the se- 
quence of an endothelin converting enzyme isolated from bo- 
vine adrenal cortex. Although there is identity with our bovine 
sequence over almost the entire coding region, there is a com- 
plete lack of homology in the N-terminal 32 amino acid residues 
of the sequence. 
By carefully analyzing the corresponding regions of ours and 
the published sequences, we observed the following: (1) the 
corresponding coding region between our bovine, and the 
human and rat sequences are highly conserved and differ by 
only 4 and 2 amino acid residues, respectively; (2) the nucleo- 
tide sequence published by Yanagisawa and coworkers [23] 
contains a perfect consensus 3’ splice junction between posi- 
tions 205 and 219 (T/C > 11 N C/T AG); (3) the nucleotide 
sequence between positions 1 and 219 is in excellent agreement 
(> 80% identity) with intronic sequences that we generated with 
human genomic clones of the endothelin converting enzyme 
(data not shown). 
We therefore conclude, that this region of the sequence pub- 
lished by Yanagisawa is due to a misinterpretation of incorpo- 
rated intronic sequences and does not reflect the authentic 
amino acid sequence. 
We are not surprised, that the recombinant enzyme gener- 
ated by Yanagisawa [23] displaying unrelated N-terminal in- 
tronic sequences i  nevertheless an active and specific endothe- 
lin converting enzyme. During the course of our studies we 
generated asecreted version of the recombinant enzyme lacking 
the entire N-terminal region including the membrane anchor 
domain and still obtained an active and specific enzyme (man- 
uscript in preparation). 
The zinc-chelating motif HEXXH, typical for metallopro- 
teases and the putative active site, starts at amino acid position 
590 (bovine: 591). The amino acid sequence between position 
52 (53) and 72 (73) contains a very hydrophobic stretch which 
most probably represents the membrane anchor of ECE-1 and 
identifies it as a class II transmembrane protein [24]. Significant 
homologies were detected with NEP 3.4.24.11 [25] (37% iden- 
tity) and Kell blood group antigen [26] (25%). This homology 
places ECE in the evolutionary subfamily Ml3 [27] of the 
‘zincin’ [28] metalloproteases. Several residues which have been 
shown to be involved in zinc and ligand-binding by NEP 
3.4.24.11 [29-361 have been conserved in the ECEs and are 
indicated in Fig. 2 with bold letters. There are ten potential 
N-linked glycosylation sites in ECE, three of which appear at 
equivalent positions compared with NEP 3.4.24.11 [29] (sites 1, 
5 and 10). The existence of ten potential glycosylation sites in 
Table 2 
Enzymatic omparison of recombinant and natural ECE 
Natural Recombinant 
(bovine) (human) 
I&, (phosphoramidon) 
in PM 6 8 
K, (Big-ET-l) 
in ,uM 
Big-ET- 1 
Big-ET-2 
Big-ET-3 
(Conversion of Big-ET-l 
was set to 100%) 
18 23 
100% 100% 
10% 10% 
0% 0% 
Natural ECE was purified from FBHE cells. Recombinant human ECE 
was expressed in CHO-cells. Results from at least 2 independent sets 
of experiments are shown. ECE-activity was measured as described in 
section 2. IC, is the phosphoramidon concentration at which ECE 
activity is inhibited by 50%. K,,,, Michaelis-Menten constant. 
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the ECE-1 sequence is compatible with a strong glycosylation 
of the native protein so that a molecular weight for the glycosyl- 
ated protease monomer of 120 kDa appears reasonable. Of the 
fourteen cysteine-residues, ten occur at equivalent positions 
compared with NEP 3.4.24.11 [29] and are probably involved 
in disulfide bridges. 
Recombinant human ECE-1 (rh-ECE-1) was expressed in 
Xenopus laevis oocytes as well as in Chinese hamster ovary 
(CHO) cells. SP6 polymerase derived cRNA and a mock con- 
trol were each injected into 100 oocytes . After 24, 48 and 72 
h, 30 oocytes were homogenized and pelleted by centrifugation 
at 10,000 x g. ECE-1 activity in mock-injected oocytes was de- 
termined to be 12, 22 and 28 PUlmg for the three time points 
and 75, 132 and 137 for the cRNA-injected oocytes respec- 
tively. The increase in ECE-1 activity was more than fivefold 
and clearly demonstrates that cRNA from the cloned cDNA 
leads to active recombinant enzyme in this system. The ECE-1 
activity found in mock-injected oocytes may be important since 
in mice it has been recently shown that ET-l is a morphogen 
[8] and the presence of an ET-receptor subtype has been dem- 
onstrated in Xenopus [37]. CHO cells were transfected with a 
plasmid construct which expressed ECE- 1 under the control of 
the strong CMV intermediate arly gene promoter. Stable cell 
lines were established and a pool of several clones was grown 
to lo9 cells. Cells were harvested and ECE-1 was recovered 
from MonoQ (as described in Table 1). We could not detect any 
ECE-1 activity in parallel experiments with untransfected 
CHO-cells. The specific enzymatic activity of rh-ECE-1 and its 
K,,, value were determined (see Table 2). The data suggest hat 
the characterized enzyme represents the functional human en- 
dothelin converting enzyme ECE-I with a very similar catalytic 
activity. These preparations show ECE-l-activity in membra- 
neous fractions with no detectable activity in the supernatant 
of the cells or in the cytosol. This activity distribution is consis- 
tent with ECE-1 being an integral membrane protein class II 
as deduced from its sequence. 
However, cytosolic ECE-activities not further identified so 
far have also been described [9]. Since we find that in bovine 
endothelial cells the only reproducible ECE-1 activity has been 
in the membraneous fraction, questions arise as to whether 
other, possibly isoenzymes with ECE-l-activity, may exist and 
to which extent they may contribute to the release of ET-l. 
With the knowledge of the DNA-sequence of ECE, questions 
relating to the physiological and pathophysiological role of 
ECE might be approached by oligonucleotide directed antis- 
ense experiments or knock-out of the ECE gene in mice. 
The rat [22], bovine ([23] and our work) and human ECEs 
have been cloned and expressed. However, the substrate speci- 
ficity of the respective recombinant enzymes is controversial. 
Whereas the activity of the cloned rat enzyme is identical to the 
activity of our cloned human enzyme (poor conversion of Big- 
ET-2; Big-ET-3) the cloned bovine enzyme does have high 
conversion activity towards Big-ET-2 and Big-ET-3. It seems 
possible that species differences are responsible for this differ- 
ence in ECE-activity. However, bovine ECE from endothelial 
cells does not show high activity towards Big-ET-2 and Big-ET- 
3 ([39] and our unpublished data). We speculated that differ- 
ences in membrane anchoring between the recombinant human 
and rat ECE on one hand and the recombinant bovine ECE of 
Xu and coworkers [23] on the other, resulting from the different 
amino termini, might account for the substrate specificity. This 
knt 
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Fig. 3. RNA levels in different tissues determined by Northern blot 
analysis. A human tissue Northern blot was hybridized under standard 
conditions with a 32P-labelled human ECE-1 cDNA probe as specified 
in section 2. The lanes represent: (M) molecular weight marker, 
(1) heart, (2) brain, (3) placenta, (4) lung, (5) liver, (6) skeletal muscle, 
(7) kidney and (8) pancreas; knt: kilo nucleotides. 
view is corroborated by our expressing the extracellular domain 
of human ECE without any membrane anchor (manuscript in 
preparation). We could demonstrate that this truncated ECE 
had the same behaviour towards Big-ET-2 and Big-ET-3 as the 
full size human ECE. We also analyzed whether purification 
and assay conditions might account for these differences in 
activity of the recombinant enzymes. Under all circumstances, 
we have been unable to demonstrate fficient cleavage of Big- 
ET-2 and Big-ET-3 compared to Big-ET-l with the recombi- 
nant human ECE- 1. The processing of these two peptides under 
physiological conditions is therefore probably carried out by 
other, yet unidentified enzymes. 
A 4.6 kb ECE-1 mRNA was detected by Northern blot 
analysis in various human tissues (Fig. 3), the strongest expres- 
sion being seen in lung, pancreas and placenta. Almost no 
transcription was detected in brain. The strong expression of 
ECE-1 message in lung and placenta can be rationalized for 
these endothelium-rich organs. The observed RNA level in 
pancreas is in accordance with the high concentration of other 
peptidases and prohormone converting proteases found in this 
organ; however, its potential role in the pancreas requires clar- 
ification. Reports from other groups extend these findings with 
respect to the relative abundance of ET-receptor mRNA in 
different tissues. mRNA specific for the smooth muscle cell 
receptor type ET, was found to be strongly represented in 
human lung, whereas the endothelial type ET,-mRNA was also 
found in human lung and in placenta, but only in low amounts 
in pancreas [27]. This makes an autocrine or paracrine mode 
of ET-action in these tissues, with the possible exception of the 
pancreas, likely. 
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